Research & Literature

Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels.

Zanotti R, Lombardo C, Passalacqua G, et al.

The Journal of allergy and clinical immunology 2015; (136(1)):135-9.

Mast Cell Activation Syndrome.

Frieri M

Clinical reviews in allergy & immunology 2018; (54(3)):353-365 doi:10.1007/s12016-015-8487-6.

H1-antihistamines for primary mast cell activation syndromes: a systematic review.

Nurmatov UB, Rhatigan E, Simons FE, Sheikh A

Allergy 2015; (70(9)):1052-61 doi:10.1111/all.12672.

Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.

Reichard KK, Chen D, Pardanani A, et al.

American journal of clinical pathology 2015; (144(3)):493-502 doi:10.1309/AJCPSGQ71GJQQACL.

Hymenoptera Allergy and Mast Cell Activation Syndromes.

Bonadonna P, Bonifacio M, Lombardo C, Zanotti R

Current allergy and asthma reports 2016; (16(1)):5 doi:10.1007/s11882-015-0582-5.

Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Rossini M, Zanotti R, Orsolini G, et al.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2016; (27(8)):2411-21 doi:10.1007/s00198-016-3539-1.

Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.

Jawhar M, Schwaab J, Horny HP, et al.

European journal of clinical investigation 2016; (46(5)):392-7 doi:10.1111/eci.12607.

Current and future therapies for treating chronic spontaneous urticaria.

Maurer M, Vena GA, Cassano N, Zuberbier T

Expert opinion on pharmacotherapy 2016; (17(8)):1131-9 doi:10.1517/14656566.2016.1159298.

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.

González-de-Olano D, Matito A, Orfao A, Escribano L

F1000Research 2016; (5()):2666 doi:10.12688/f1000research.9565.1.

Mast Cell Clonal Disorders: Classification, Diagnosis and Management.

Onnes MC, Tanno LK, Elberink JN

Current treatment options in allergy 2016; (3(4)):453-464 doi:10.1007/s40521-016-0103-3.

Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.

Van den Poel B, Kochuyt AM, Del Biondo E, et al.

Acta clinica Belgica 2017; (72(2)):123-129 doi:10.1080/17843286.2017.1293312.

Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.

Conde-Fernandes I, Sampaio R, Moreno F, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2017; (13()):21 doi:10.1186/s13223-017-0193-x.

Pharmacotherapy of mast cell disorders.

Gülen T, Akin C

Current opinion in allergy and clinical immunology 2017; (17(4)):295-303 doi:10.1097/ACI.0000000000000377.

A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.

Carter MC, Desai A, Komarow HD, et al.

The Journal of allergy and clinical immunology 2018; (141(1)):180-188.e3 doi:10.1016/j.jaci.2017.05.036.

Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.

Broesby-Olsen S, Vestergaard H, Mortz CG, et al.

Allergy 2018; (73(1)):230-238 doi:10.1111/all.13237.

Corticosteroids in management of anaphylaxis; a systematic review of evidence.

Liyanage CK, Galappatthy P, Seneviratne SL

European annals of allergy and clinical immunology 2017; (49(5)):196-207 doi:10.23822/EurAnnACI.1764-1489.15.

Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected.

Bonadonna P, Zanotti R, Pagani M, et al.

The journal of allergy and clinical immunology. In practice 2018; (6(4)):1368-1372 doi:10.1016/j.jaip.2017.11.025.

Gastrointestinal Involvement in Mast Cell Activation Disorders.

Hsieh FH

Immunology and allergy clinics of North America 2018; (38(3)):429-441 doi:10.1016/j.iac.2018.04.008.

Hymenoptera Anaphylaxis as a Clonal Mast Cell Disorder.

Bonadonna P, Scaffidi L

Immunology and allergy clinics of North America 2018; (38(3)):455-468 doi:10.1016/j.iac.2018.04.010.

Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.

Castells M, Butterfield J

The journal of allergy and clinical immunology. In practice 2019; (7(4)):1097-1106 doi:10.1016/j.jaip.2019.02.002.

The Role of KIT Mutations in Anaphylaxis.

Coulson E, Zhou S, Akin C

Current allergy and asthma reports 2019; (19(6)):31 doi:10.1007/s11882-019-0863-5.

Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.

Valent P, Bonadonna P, Hartmann K, et al.

International archives of allergy and immunology 2019; (180(1)):44-51 doi:10.1159/000501079.

Mastocytosis presenting as insect anaphylaxis: gender differences and natural history.

Alvarez-Twose I, Matito A

Current opinion in allergy and clinical immunology 2019; (19(5)):468-474 doi:10.1097/ACI.0000000000000567.

Tryptase values in anaphylaxis and insect allergy.

Bonadonna P, Scaffidi L, Boni E

Current opinion in allergy and clinical immunology 2019; (19(5)):462-467 doi:10.1097/ACI.0000000000000569.

Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection.

Jarkvist J, Salehi C, Akin C, Gülen T

Allergy 2020; (75(1)):169-177 doi:10.1111/all.13980.

Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.

Shaker MS, Wallace DV, Golden DBK, et al.

The Journal of allergy and clinical immunology 2020; (145(4)):1082-1123 doi:10.1016/j.jaci.2020.01.017.

[Mast cell activation syndrome. About a clinical case].

Cardona R, Muñoz-Ávila MA, Gómez-Henao C, et al.

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2019; (66(4)):504-509 doi:10.29262/ram.v66i4.587.

Epinephrine in the Management of Anaphylaxis.

Brown JC, Simons E, Rudders SA

The journal of allergy and clinical immunology. In practice 2020; (8(4)):1186-1195 doi:10.1016/j.jaip.2019.12.015.

World allergy organization anaphylaxis guidance 2020.

Cardona V, Ansotegui IJ, Ebisawa M, et al.

The World Allergy Organization journal 2020; (13(10)):100472 doi:10.1016/j.waojou.2020.100472.

Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic.

Bilò MB, Braschi MC, Piga MA, et al.

The journal of allergy and clinical immunology. In practice 2021; (9(2)):702-708 doi:10.1016/j.jaip.2020.11.030.

Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.

Valent P, Akin C, Nedoszytko B, et al.

International journal of molecular sciences 2020; (21(23)) doi:10.3390/ijms21239030.

Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.

Matito A, Escribese MM, Longo N, et al.

Journal of investigational allergology & clinical immunology 2021; (31(6)):461-470 doi:10.18176/jiaci.0675.

Use and Interpretation of Acute and Baseline Tryptase in Perioperative Hypersensitivity and Anaphylaxis.

Vitte J, Sabato V, Tacquard C, et al.

The journal of allergy and clinical immunology. In practice 2021; (9(8)):2994-3005 doi:10.1016/j.jaip.2021.03.011.

Diagnosis of Primary Mast Cell Disorders in Anaphylaxis: Value of KIT D816V in Peripheral Blood.

De Puysseleyr LP, Ebo DG, Elst J, et al.

The journal of allergy and clinical immunology. In practice 2021; (9(8)):3176-3187.e3 doi:10.1016/j.jaip.2021.04.062.

Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.

Muñoz-González JI, García-Montero AC, Orfao A, Álvarez-Twose I

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2021; (127(4)):427-434 doi:10.1016/j.anai.2021.07.014.

Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond.

Nguyen SMT, Rupprecht CP, Haque A, et al.

International journal of molecular sciences 2021; (22(15)) doi:10.3390/ijms22157785.

Systemic Mastocytosis: Multidisciplinary Approach.

Zanotti R, Tanasi I, Crosera L, et al.

Mediterranean journal of hematology and infectious diseases 2021; (13(1)):e2021068 doi:10.4084/MJHID.2021.068.

Precision Medicine in Systemic Mastocytosis.

Nicolosi M, Patriarca A, Andorno A, et al.

Medicina (Kaunas, Lithuania) 2021; (57(11)) doi:10.3390/medicina57111135.

CSACI position statement: transition recommendations on existing epinephrine autoinjectors.

Li LDX, Abrams EM, Lavine E, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2021; (17(1)):130 doi:10.1186/s13223-021-00634-2.

A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020).

Li X, Ma Q, Yin J, et al.

Frontiers in pharmacology 2022; (13()):845689 doi:10.3389/fphar.2022.845689.

Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium.

Pyatilova P, Akin C, Alvarez-Twose I, et al.

The journal of allergy and clinical immunology. In practice 2022; (10(8)):2015-2024 doi:10.1016/j.jaip.2022.05.037.

Mast cell activation syndrome and the link with long COVID.

Arun S, Storan A, Myers B

British journal of hospital medicine (London, England : 2005) 2022; (83(7)):1-10 doi:10.12968/hmed.2022.0123.

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.

Navarro-Navarro P, Álvarez-Twose I, Pérez-Pons A, et al.

Allergy 2023; (78(5)):1347-1359 doi:10.1111/all.15584.

Venom Anaphylaxis: Decision Points for a More Aggressive Workup.

Bonadonna P, Korosec P, Nalin F, Golden DBK

The journal of allergy and clinical immunology. In practice 2023; (11(7)):2024-2031 doi:10.1016/j.jaip.2023.04.016.

Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).

Ruëff F, Bauer A, Becker S, et al.

Allergologie select 2023; (7()):154-190 doi:10.5414/ALX02430E.

Hereditary Alpha Tryptasemia: Validation of a Single-Well Multiplex Digital Droplet PCR Assay in a Cohort of Symptomatic Patients.

Alheraky A, Wierenga ATJ, Simpelaar A, et al.

Clinical chemistry 2024; (70(2)):425-433 doi:10.1093/clinchem/hvad206.

Anaphylaxis: A 2023 practice parameter update.

Golden DBK, Wang J, Waserman S, et al.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2024; (132(2)):124-176 doi:10.1016/j.anai.2023.09.015.

Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders.

Beyens M, Toscano A, Ebo D, et al.

Diagnostics (Basel, Switzerland) 2023; (13(24)) doi:10.3390/diagnostics13243662.

The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients.

Degboé Y, Severino-Freire M, Couture G, et al.

The journal of allergy and clinical immunology. In practice 2024; (12(5)):1306-1312 doi:10.1016/j.jaip.2024.02.021.

High burden of clonal mast cell disorders and hereditary α-tryptasemia in patients who need Hymenoptera venom immunotherapy.

Korošec P, Sturm GJ, Lyons JJ, et al.

Allergy 2024; (79(9)):2458-2469 doi:10.1111/all.16084.

Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy.

McMurray JC, Pacheco CS, Schornack BJ, et al.

Blood 2024; (144(4)):408-419 doi:10.1182/blood.2023023347.

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

Gotlib J, Gerds AT, Abdelmessieh P, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2024; (22(2 D)).

Diagnosis and management of anaphylaxis.

Hearrell M, Anagnostou A

Journal of food allergy 2020; (2(1)):64-68 doi:10.2500/jfa.2020.2.200001.

Mast Cell Disorders and Hymenoptera Venom-Triggered Anaphylaxis: Evaluation and Management.

Boggs NA, Tanasi I, Hartmann K, et al.

The journal of allergy and clinical immunology. In practice 2025; (13(1)):40-48 doi:10.1016/j.jaip.2024.08.034.

Systematic review of omalizumab for refractory clonal and non-clonal mast cell activation syndrome.

Matheny MV, Craig T, Al-Shaikhly T

Allergy and asthma proceedings 2025; (46(1)):11-18 doi:10.2500/aap.2025.46.240076.

Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specified.

Ballul T, Sabato V, Valent P, et al.

EClinicalMedicine 2025; (80()):103043 doi:10.1016/j.eclinm.2024.103043.

Confirmed Systemic Mastocytosis in a Pediatric Patient With Widespread Cutaneous Symptoms.

Cahill JA, Suresh S, Livingston JR

Pediatrics 2025; doi:10.1542/peds.2024-067915.

Management of Bone Health in Adult Mastocytosis.

Degboé Y, Nezzar C, Alary P, et al.

Current osteoporosis reports 2025; (23(1)):10 doi:10.1007/s11914-025-00901-w.

High-sensitivity KIT D816V variation analysis by droplet digital polymerase chain reaction: The reference laboratory perspective.

Shean RC, Hellwig S, Saadalla A, et al.

American journal of clinical pathology 2025; (164(2)):145-149 doi:10.1093/ajcp/aqaf008.

AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

Aziz Q, Harris LA, Goodman BP, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

Utility of tryptase genotyping in the screening, diagnosis, and management of systemic mastocytosis.

McMurray JC, Schornack BJ, Villar J, et al.

Frontiers in allergy 2025; (6()):1599358 doi:10.3389/falgy.2025.1599358.

Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis.

Nöldeke P, Schmalz O, Kvasnicka H, et al.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):40 doi:10.1186/s13223-025-00986-z.

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

Reiter A, Rossignol J, Deininger MW, et al.

The journal of allergy and clinical immunology. In practice 2026; (14(1)):44-52 doi:10.1016/j.jaip.2025.10.034.

Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach.

Lee E, Picard M

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2025; (21(1)):49 doi:10.1186/s13223-025-00998-9.

Overview of allergic disease: Anaphylaxis - WAO White Book on Allergy 2026 - 2.11.

Cardona V

The World Allergy Organization journal 2026; (19(3)):101338 doi:10.1016/j.waojou.2026.101338.

Definition of Competencies for Allergology Specialty/Subspecialty Training in Mast Cell Disorders in Europe: An EAACI Position Paper.

Rama TA, Gulen T, Brockow K, et al.

Allergy 2026; (81(8)):2713-2725 doi:10.1111/all.70344.

Systemic Mastocytosis: Molecular Pathophysiology, WHO Diagnostic Framework, and KIT-Directed Targeted Therapies.

Alati C, Greve MB, Porto G, et al.

Cancers 2026; (18(14)) doi:10.3390/cancers18142205.